ACTIVE

UCB PHARMA

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result4,2 Md €+347,5 %over 1 year

Revenue4,6 Md €+9,8 %over 1 year

Equity16,2 Md €+31,0 %over 1 year

Workforce1 960,6 ETP+12,3 %over 1 year

Identity

Source · BCE/KBO

UCB PHARMA is a Public limited company incorporated in 1968. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Anderlecht. It employs on average 1 960,6 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0403.096.168
Incorporation: 01/02/1968
Legal form: Public limited company
Registered office: Allée de la Recherche 60
1070 Anderlecht · BruxellesSee on map
Contributed capital: 7 804 773 810,00 €
Latest accounts: 31/12/2025
Average workforce: 1 960,6 ETP

Activities (NACE)

21201Manufacture of pharmaceutical preparations· main 21201Manufacture of pharmaceutical preparations 24421Aluminium production 46460Wholesale of pharmaceutical goods 46460Wholesale of pharmaceutical goods 51460Air transport

Joint committees (2)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debtsHigh revenue

Financials

Source · NBB, 21 filings

Trend over 18 financial years

	2025		2024		2023		2022		2021
Income statement
Revenue	4,6 Md €	+9.8%	4,2 Md €	+32.6%	3,2 Md €	-3.6%	3,3 Md €	-4.0%	3,4 Md €
EBITDA	451,1 M €	-59.5%	1,1 Md €	+23.7%	899,9 M €	-20.3%	1,1 Md €	+44.7%	780,8 M €
Operating result	334,7 M €	-67.4%	1 Md €	+17.7%	872,8 M €	-11.5%	985,7 M €	+47.4%	668,9 M €
Net result	4,2 Md €	+347%	947,4 M €	+1.0%	938,1 M €	-1.1%	948,1 M €	+54.8%	612,6 M €
Balance sheet
Equity	16,2 Md €	+31.0%	12,4 Md €	+5.1%	11,8 Md €	+5.2%	11,2 Md €	+15.1%	9,7 Md €
Total assets	20,7 Md €	+26.4%	16,4 Md €	+8.0%	15,2 Md €	+4.3%	14,6 Md €	+24.4%	11,7 Md €
Cash	7,9 M €	-28.8%	11,1 M €	+43.9%	7,7 M €	-54.4%	16,8 M €	+2272%	710,3 k €
Debts	4,4 Md €	+11.8%	3,9 Md €	+18.1%	3,3 Md €	+0.2%	3,3 Md €	+73.9%	1,9 Md €
Other
Workforce	1 960,6 ETP	+12.3%	1 746,4 ETP	+19.3%	1 464,4 ETP	+6.8%	1 371,1 ETP	+3.4%	1 326,1 ETP

Valuation

Indicative valuation

As an indication, this company is worth

more than 1.000 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 17 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Jean-Christophe TELLIER	Chairman of the board of directors17/03/2014 → 09/05/2029
Caroline VANCOILLIE	Director09/05/2018 → 10/05/2028
Kirsten LUND-JÜRGENSEN	Director18/07/2019 → 10/05/2028

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Charl VAN ZYL	Director10/05/2017 → 01/07/2023
Benoit STEVENS	Director15/01/2016 → 19/04/2018

Other companies at this address

Allée de la Recherche 60 1070 Anderlecht

Company	CBE no.
Fondation Emmanuel Janssen● Active	0408.369.901
U C B● Active	0403.053.608
UCB Belgium● Active	0402.040.254
UCB BIOPHARMA● Active	0543.573.053
UCB Developed Brands● Active	1017.533.562
UCB Fipar● Active	0403.198.811
UCB Pillar 2● Active	1011.675.752
UCB Ventures● Active	0667.816.096
UCB Ventures Belgium● Active	0668.388.891
UNITE TVA UCB● Active	0820.436.985

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Full model	Full model	Full model	Full model	Full model	Full model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	19/05/2026	19/05/2025	06/08/2024	17/05/2023	23/05/2022	30/04/2021
General meeting	13/05/2026	14/05/2025	08/05/2024	10/05/2023	11/05/2022	27/04/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 21 filings

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2025	13/05/2026	19/05/2026	French	PDF
Full model	31/12/2024	14/05/2025	19/05/2025	French	PDF
Full modelCorrection	31/12/2023	08/05/2024	06/08/2024	French	PDF
Full model	31/12/2023	08/05/2024	13/05/2024	French	PDF
Full model	31/12/2022	10/05/2023	17/05/2023	French	PDF
Full model	31/12/2021	11/05/2022	23/05/2022	French	PDF
Full model	31/12/2020	27/04/2021	30/04/2021	French	PDF
Full model	31/12/2019	13/05/2020	18/05/2020	French	PDF
Full model	31/12/2018	08/05/2019	10/05/2019	French	PDF
Full model	31/12/2017	09/05/2018	28/05/2018	French	PDF
Full model	31/12/2016	10/05/2017	22/05/2017	French	PDF
Full model	31/12/2015	11/05/2016	24/05/2016	French	PDF
Full model	31/12/2014	13/05/2015	29/05/2015	French	PDF
Full model	31/12/2013	14/05/2014	08/08/2014	French	PDF
Full model	31/12/2012	28/06/2013	02/08/2013	French	PDF
Full model	31/12/2011	14/05/2012	20/06/2012	French	PDF
Full model	31/12/2010	11/05/2011	12/05/2011	French	PDF
Full model	31/12/2009	12/05/2010	18/05/2010	French	PDF
Full model	31/12/2008	13/05/2009	29/06/2009	French	PDF
Full model	31/12/2007	13/05/2008	13/06/2008	French	PDF
Full model	31/12/2006	09/05/2007	31/05/2007	French	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

more than 1.000 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 17 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Jean-Christophe TELLIER	Chairman of the board of directors17/03/2014 → 09/05/2029
Caroline VANCOILLIE	Director09/05/2018 → 10/05/2028
Kirsten LUND-JÜRGENSEN	Director18/07/2019 → 10/05/2028

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Charl VAN ZYL	Director10/05/2017 → 01/07/2023
Benoit STEVENS	Director15/01/2016 → 19/04/2018

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates10/09/2026
Nomination d'un administrateur - Fin de mandat d'un administrateur
PDF
Mandates17/10/2025
DEMISSIONS, NOMINATIONS
PDF
Mandates26/08/2024
DEMISSIONS, NOMINATIONS
PDF
Mandates04/08/2023
DEMISSIONS, NOMINATIONS
PDF
Mandates04/08/2023
DEMISSIONS, NOMINATIONS
PDF
Capital / shares28/07/2022
CAPITAL, ACTIONS
PDF
Mandates23/06/2022
DEMISSIONS, NOMINATIONS
PDF
Mandates09/07/2021
DEMISSIONS, NOMINATIONS
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts

Year

Identity

Incorporation

Name

Registered office

Annual accounts

Filings18 filings

Mandates

Jean-Christophe TELLIER

Caroline VANCOILLIE

Kirsten LUND-JÜRGENSEN

Charl VAN ZYL

Cleo RICCI

Benoit STEVENS

Ismail KOLA

Detlef THIELGEN

Mark McDADE

Fabrice ENDERLIN

Anna S. RICHO

Robert TRAINOR

Show the 8 other mandates

19681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

UCB PHARMA

Allée de la Recherche 60, 1070 Anderlecht

Chairman of the board of directors

Director

CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE

Registered address	Period	Source
Allée de la Recherche 60, 1070 AnderlechtCurrent	accounts 2021 → 2025	Accounts 2025 · 2026-00115119

Company names

Source · NBB annual accounts, CBE

Name	Period	Source
UCB PHARMACurrent	accounts 2021 → 2025	Accounts 2025 · 2026-00115119

Events

2025
Annual accounts 20254,2 Md €↑
2024
Annual accounts 2024947,4 M €↑
26/07/2024
nominationMyriam Juckler · déléguée chargée de la gestion journalière
08/05/2024
nominationSébastien Schueremans · commissaire aux comptes (représentant permanent de Mazars Bedrijfsrevisoren - Réviseurs d'Entreprises BV/SRL)
2023
Annual accounts 2023938,1 M €↓
10/05/2023
reconductionJean-Christophe Tellier · administrateur
10/05/2023
reconductionCharl van Zyl · administrateur
2022
Annual accounts 2022948,1 M €↑
15/07/2022
augmentation_capital
15/07/2022
apport
11/05/2022
reconductionKirsten Lund-Jürgensen · administrateur
11/05/2022
reconductionCaroline Vancoillie · administrateur
2021
Annual accounts 2021612,6 M €↑
2020
Annual accounts 2020574,8 M €↑
16/10/2020
reconductionGeoffroy Folie · délégué à la gestion journalière
2019
Annual accounts 2019444,3 M €↑
2018
Annual accounts 2018439,6 M €↓
2017
Annual accounts 2017566,7 M €↑
2016
Annual accounts 2016491,7 M €↑
2015
Annual accounts 2015-30,5 M €↓
2014
Annual accounts 201434,3 M €↓
2013
Annual accounts 201365,8 M €↑
2012
Annual accounts 2012-256,5 M €↓
2011
Annual accounts 2011-24,5 M €↓
2010
Annual accounts 2010217,2 M €↑
2009
Annual accounts 2009-193,3 M €↑
2008
Annual accounts 2008-197,8 M €
01/02/1968
IncorporationPublic limited company

UCB PHARMA

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline

Registered offices

Company names

Events